Cbl Exposes Its RING Finger

Overview

Journal Nat Struct Mol Biol

Specialties Cell Biology
Molecular Biology

Date 2012 Feb 4

PMID 22301873

Citations 13

Authors

Stephen C Kales

Philip E Ryan

Stanley Lipkowitz

Affiliations

Soon will be listed here.

Citing Articles

Zooming into the structure-function of RING finger proteins for anti-cancer therapeutic applications.

George M, Masamba P, Iwalokun B, Kappo A Am J Cancer Res. 2023; 13(7):2773-2789.

PMID: 37559981 PMC: 10408477.

Overexpression of Cancer Upregulated Gene 2 (CUG2) Decreases Spry2 Through c-Cbl, Leading to Activation of EGFR and β-Catenin Signaling.

Yawut N, Kaewpiboon C, Budluang P, Cho I, Kaowinn S, Koh S Cancer Manag Res. 2020; 12:10243-10250.

PMID: 33116878 PMC: 7573319. DOI: 10.2147/CMAR.S271109.

Depletion of Csk preferentially reduces the protein level of LynA in a Cbl-dependent manner in cancer cells.

Kuga T, Yamane Y, Hayashi S, Taniguchi M, Yamaguchi N, Yamagishi N Sci Rep. 2020; 10(1):7621.

PMID: 32376886 PMC: 7203244. DOI: 10.1038/s41598-020-64624-x.

Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene.

Nadeau S, An W, Mohapatra B, Mushtaq I, Bielecki T, Luan H J Biol Chem. 2017; 292(9):3666-3682.

PMID: 28082680 PMC: 5339751. DOI: 10.1074/jbc.M116.772723.

Activation of the E3 ubiquitin ligase Parkin.

Caulfield T, Fiesel F, Springer W Biochem Soc Trans. 2015; 43(2):269-74.

PMID: 25849928 PMC: 4859148. DOI: 10.1042/BST20140321.

References

Lupher Jr M, Reedquist K, Miyake S, Langdon W, Band H . A novel phosphotyrosine-binding domain in the N-terminal transforming region of Cbl interacts directly and selectively with ZAP-70 in T cells. J Biol Chem. 1996; 271(39):24063-8. DOI: 10.1074/jbc.271.39.24063. View

Zheng N, Wang P, Jeffrey P, Pavletich N . Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell. 2000; 102(4):533-9. DOI: 10.1016/s0092-8674(00)00057-x. View

Kobashigawa Y, Tomitaka A, Kumeta H, Noda N, Yamaguchi M, Inagaki F . Autoinhibition and phosphorylation-induced activation mechanisms of human cancer and autoimmune disease-related E3 protein Cbl-b. Proc Natl Acad Sci U S A. 2011; 108(51):20579-84. PMC: 3251137. DOI: 10.1073/pnas.1110712108. View

Lorick K, Jensen J, Fang S, Ong A, Hatakeyama S, Weissman A . RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci U S A. 1999; 96(20):11364-9. PMC: 18039. DOI: 10.1073/pnas.96.20.11364. View

Meng W, Sawasdikosol S, Burakoff S, Eck M . Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase. Nature. 1999; 398(6722):84-90. DOI: 10.1038/18050. View

Lill N, Douillard P, Awwad R, Ota S, Lupher Jr M, Miyake S . The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor. J Biol Chem. 2000; 275(1):367-77. DOI: 10.1074/jbc.275.1.367. View

Yokoi N, Fujiwara Y, Wang H, Kitao M, Hayashi C, Someya T . Identification and functional analysis of CBLB mutations in type 1 diabetes. Biochem Biophys Res Commun. 2008; 368(1):37-42. DOI: 10.1016/j.bbrc.2008.01.032. View

Scott R, Eketjall S, Aineskog H, Ibanez C . Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase. J Biol Chem. 2005; 280(14):13442-9. DOI: 10.1074/jbc.M500507200. View

Fang D, Wang H, Fang N, Altman Y, Elly C, Liu Y . Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells. J Biol Chem. 2000; 276(7):4872-8. DOI: 10.1074/jbc.M008901200. View

10.

Joazeiro C, Wing S, Huang H, Leverson J, Hunter T, Liu Y . The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science. 1999; 286(5438):309-12. DOI: 10.1126/science.286.5438.309. View

11.

Wiesner S, Ogunjimi A, Wang H, Rotin D, Sicheri F, Wrana J . Autoinhibition of the HECT-type ubiquitin ligase Smurf2 through its C2 domain. Cell. 2007; 130(4):651-62. DOI: 10.1016/j.cell.2007.06.050. View

12.

Kales S, Ryan P, Nau M, Lipkowitz S . Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Res. 2010; 70(12):4789-94. PMC: 2888780. DOI: 10.1158/0008-5472.CAN-10-0610. View

13.

Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A . A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J. 2002; 21(3):303-13. PMC: 125825. DOI: 10.1093/emboj/21.3.303. View

14.

Chiang J, Jang I, Hodes R, Gu H . Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. J Clin Invest. 2007; 117(4):1029-36. PMC: 1810570. DOI: 10.1172/JCI29472. View

15.

Fang D, Liu Y . Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat Immunol. 2001; 2(9):870-5. DOI: 10.1038/ni0901-870. View

16.

Kassenbrock C, Anderson S . Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations. J Biol Chem. 2004; 279(27):28017-27. DOI: 10.1074/jbc.M404114200. View

17.

Sanna S, Pitzalis M, Zoledziewska M, Zara I, Sidore C, Murru R . Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis. Nat Genet. 2010; 42(6):495-7. PMC: 3786343. DOI: 10.1038/ng.584. View

18.

Deshaies R, Joazeiro C . RING domain E3 ubiquitin ligases. Annu Rev Biochem. 2009; 78:399-434. DOI: 10.1146/annurev.biochem.78.101807.093809. View

19.

Lipkowitz S, Weissman A . RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer. 2011; 11(9):629-43. PMC: 3542975. DOI: 10.1038/nrc3120. View

20.

Levkowitz G, Waterman H, Ettenberg S, Katz M, Tsygankov A, Alroy I . Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 2000; 4(6):1029-40. DOI: 10.1016/s1097-2765(00)80231-2. View